The new SPAC intends to target life science companies in North America and Singapore with a particular emphasis on companies developing assets and next-generation platform technologies with broad applicability. ALSP Orchid I is led by Chief Executive Officer and President Thong Q. Le, Chief Financial Officer Ian A. W. Howes, Chief Development Officer Kendall M. Moher Ph.D., Chief Operating Officer Andras T. Forgacs, Chief Business Officer Kevin T. Chow Ph.D., Chairman Nominee of the Board of Directors Bruce L.A. Carter, Ph.D., and Senior Advisers Randall C. Schatzman, Ph.D., and Philip Yeo Liat Kok.
Total SPAC deal count for 2021 year-to-date is now 551. This offering is expected to close on Tuesday, November 23.
Stifel, Nicolaus & Company, Incorporated and Nomura Securities International, Inc. are acting as the joint book-running managers for the offering. Cooley LLP is serving as Issuer’s Counsel with Glovsky and Popeo, P.C. serving as Underwriter’s Counsel. Grant Thornton LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.